RPG Life Sciences reported Q2 FY25 results with 12% revenue growth YoY at Rs 172.21 crores and 22% increase in profit before tax, along with an EBITDA margin of 27.8%. For H1 FY25, revenues reached Rs 337.63 crores, also up 12% YoY; the company remains debt-free and continues expansion in its domestic and international segments.